ATRA

Atara Biotherapeutics (ATRA)

About Atara Biotherapeutics (ATRA)

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Details

Daily high

$18.75

Daily low

$17.36

Price at open

$17.97

52 Week High

$18.95

52 Week Low

$5.00

Market cap

128.8M

Dividend yield

0.00%

Volume

66,806

Avg. volume

73,921

P/E ratio

8.15

Atara Biotherapeutics News